Results 191 to 200 of about 347,378 (341)

Patch test reactions in patients with the additional diagnosis of vitiligo [PDF]

, 2013
J. Lee, Byung‐Jin Ahn, Minsoo Noh, Ai‐Young Lee   +3 more
openalex   +1 more source

Comparison Between the 24-hour Holter Test and 72-hour Single-Lead Electrocardiogram Monitoring With an Adhesive Patch-Type Device for Atrial Fibrillation Detection: Prospective Cohort Study (Preprint)

, 2022
Soonil Kwon, So‐Ryoung Lee, Eue‐Keun Choi, Hyo‐Jeong Ahn, Hee Seok Song, Young-Shin Lee, Seil Oh, Gregory Y.H. Lip   +7 more
openalex   +1 more source

Interference of the positioning of nickel, chromium and cobalt in the results of patch tests. [PDF]

An Bras Dermatol
Duarte I, Lazzarini R, Haffner M, Silva JP.   +3 more
europepmc   +1 more source

Next‐generation proteomics improves lung cancer risk prediction

Molecular Oncology, EarlyView.
This is one of very few studies that used prediagnostic blood samples from participants of two large population‐based cohorts. We identified, evaluated, and validated an innovative protein marker model that outperformed an established risk prediction model and criteria employed by low‐dose computed tomography in lung cancer screening trials.
Megha Bhardwaj, Clara Frick, Ben Schöttker, Bernd Holleczek, Hermann Brenner   +4 more
wiley   +1 more source

Lymphocyte Transformation Tests and Patch Tests to Identify Drugs Potentially Associated With Bullous Pemphigoid Development. [PDF]

Int J Dermatol
de Nicolas-Ruanes B, Fernandez-Lozano C, Gutierrez-Canales P, Ballester-Martinez A, Rodriguez-Otero N, Martinez-Botas J, de la Hoz Caballer B, Andres-Martin A, Solano-Solares E, Gomez-Salazar Lopez-Silanes ME, Diaz-Montalvo LG, Arrebola DM, Stewart-Delcid VL, Garcia-Mouronte E, Azcarraga-Llobet C, Berna-Rico E, Ortega-Sanchez S, Fernandez-Guarino M.   +17 more
europepmc   +1 more source

Potential therapeutic targeting of BKCa channels in glioblastoma treatment

Molecular Oncology, EarlyView.
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak, Karolina Pytlak, Sandra Jaworowska, Bogusz Kulawiak, Piotr Bednarczyk   +4 more
wiley   +1 more source

Prevalence of positivity in patch tests and reactivity to substances present in the main dressings in patients with chronic leg ulcers. [PDF]

An Bras Dermatol
de Oliveira Mesquita ÍF, Pierri Carvalho Fonseca L, Rita Parise Fortes M, Amante Miot H, Patricia Fernandes Abbade L.   +4 more
europepmc   +1 more source

Positivity of contact dermatitis patch tests in an allergy and immunology dermatology service [PDF]

World Allergy Organ J, 2015
Mendes K, Castro A, Amaral C, Alonso M, Seiler T, Oliveira M, Silva E.   +6 more
europepmc   +1 more source

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

Molecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute, Júlia Huguet‐Pradell, Jordi Abril‐Fornaguera, Albert Gris‐Oliver, Alex Rialdi, Elisa Fernández‐Martínez, Carla Montironi, Vanessa Del Pozo, Peter Houghton, Laura Zanatto, Agavni Mesropian, Ieva Keraite, Swan Thung, Carolina Armengol, Pau Sancho‐Bru, Ernesto Guccione, Roser Pinyol, Josep M. Llovet   +17 more
wiley   +1 more source

Monitoring of circulating tumor DNA allows early detection of disease relapse in patients with operable breast cancer

Molecular Oncology, EarlyView.
Monitoring circulating tumor DNA (ctDNA) in patients with operable breast cancer can reveal disease relapse earlier than radiology in a subset of patients. The failure to detect ctDNA in some patients with recurrent disease suggests that ctDNA could serve as a supplement to other monitoring approaches.
Kristin Løge Aanestad, Marie Austdal, Oddmund Nordgård, Gunnar Mellgren, Satu Oltedal, Marie L. Austbø, Ylva H. Vignes, Thomas Helland, Kristin Jonsdottir, Tone H. Lende, Emilius A. M. Janssen, Bjørnar Gilje, Kjersti Tjensvoll, PBCB study group, Gunnar Mellgren, Tone Hoel Lende, Anette Heie, Kristin Viste, Anita Røyneberg Alvheim, Emiel AM Janssen, Kristin Jonsdottir, Ann Cathrine Kroksveen, Thomas Helland, Einar Gudlaugsson, Oddmund Nordgård, Satu Oltedal, Kristin Løge Aanestad, Jan Terje Kvaløy, Kirsten Lode, Kari Britt Hagen, Marie Austdal, Ylva H. Vignes, Siri Tungland Sola, Nina Egeland Amundsen, Finn Magnus Eliassen, Emeritus Ernst A Lien   +35 more
wiley   +1 more source